U.S. pharma big copyright scrapped two experimental weight loss tablets final 12 months—a at the time-everyday pill, lotiglipron, on account of elevated liver enzymes and also a twice-daily capsule, danuglipron, as a consequence of powerful side effects—but CEO Albert Bourla has stated the company is decided to “Participate in and win” duri